| 1 |
34862332 | A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity. | 2022 Mar 1 |
1 |
| 2 |
34997794 | Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis. | 2022 Jan 8 |
1 |
| 3 |
35173799 | Ocular Distribution of the Renin-Angiotensin-Aldosterone System in the Context of the SARS-CoV-2 Pandemic. | 2022 |
1 |
| 4 |
35176079 | Investigation of angiotensin-1 converting enzyme 2 gene (G8790A) polymorphism in patients of type 2 diabetes mellitus with diabetic nephropathy in Pakistani population. | 2022 |
2 |
| 5 |
35393089 | Relationship between kalemia and intensive care unit admission or death in hospitalized COVID-19 patients: A cohort study. | 2022 Feb |
1 |
| 6 |
32522617 | Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. | 2021 Jan-Feb |
1 |
| 7 |
32691370 | SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45- Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome. | 2021 Feb |
2 |
| 8 |
32917504 | Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. | 2021 Mar |
1 |
| 9 |
33039544 | Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection. | 2021 Jan 2 |
1 |
| 10 |
33188364 | COVID-19 and diabetes mellitus: from pathophysiology to clinical management. | 2021 Jan |
2 |
| 11 |
33275540 | SARS-CoV-2, ACE2 expression, and systemic organ invasion. | 2021 Feb 1 |
1 |
| 12 |
33387941 | Acute kidney injury due to COVID-19 and the circadian rhythm. | 2021 Jan |
2 |
| 13 |
33422689 | Endothelial cells and SARS-CoV-2: An intimate relationship. | 2021 Apr |
2 |
| 14 |
33458761 | Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities. | 2021 Mar 22 |
1 |
| 15 |
33537555 | Aging- and gender-related modulation of RAAS: potential implications in COVID-19 disease. | 2021 |
2 |
| 16 |
33539861 | Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). | 2021 May 1 |
2 |
| 17 |
33563197 | The Ineluctable Role of ACE-2 Receptors in SARS COV-2 Infection and Drug Repurposing as a Plausible SARS COV-2 Therapy: A Concise Treatise. | 2021 |
1 |
| 18 |
33584343 | Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. | 2021 |
1 |
| 19 |
33657582 | Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex. | 2021 Aug 1 |
1 |
| 20 |
33714595 | Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. | 2021 Apr |
1 |
| 21 |
33964216 | ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients. | 2021 Jul |
2 |
| 22 |
34010445 | Endocrine and metabolic aspects of COVID-19. | 2021 |
2 |
| 23 |
34035891 | Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. | 2021 |
1 |
| 24 |
34176080 | Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. | 2021 Dec |
1 |
| 25 |
34177593 | A Dual-Route Perspective of SARS-CoV-2 Infection: Lung- vs. Gut-specific Effects of ACE-2 Deficiency. | 2021 |
2 |
| 26 |
34195577 | A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. | 2021 Jul |
2 |
| 27 |
34356070 | Angiotensin-Converting Enzyme 2 (ACE2) as a Potential Diagnostic and Prognostic Biomarker for Chronic Inflammatory Lung Diseases. | 2021 Jul 9 |
2 |
| 28 |
34392451 | How SARS-CoV-2 might affect potassium balance via impairing epithelial sodium channels? | 2021 Sep |
4 |
| 29 |
34406302 | Cardiovascular damage due to COVID-19: what do we need to know? | 2021 |
1 |
| 30 |
34420372 | Distinct Regulation of U-ACE2 and P-ACE2 (Urinary and Plasma Angiotensin-Converting Enzyme 2) in a Japanese General Population. | 2021 Sep |
1 |
| 31 |
34501332 | ACE2, the Counter-Regulatory Renin-Angiotensin System Axis and COVID-19 Severity. | 2021 Aug 29 |
2 |
| 32 |
34596976 | Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2. | 2021 Apr |
1 |
| 33 |
34642634 | Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury. | 2021 Oct |
1 |
| 34 |
34667599 | Endothelial dysfunction and COVID-19 (Review). | 2021 Dec |
2 |
| 35 |
34673795 | Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. | 2021 |
1 |
| 36 |
34718258 | Comorbidities and Syndemics in the COVID-19 Age: Challenges and Opportunities for Bringing Separated Branches of Medicine Closer to Each Other. | 2021 Spring-Summer |
1 |
| 37 |
34806090 | Hypertension and its management in COVID-19 patients: The assorted view. | 2021 Dec |
3 |
| 38 |
34867390 | Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells. | 2021 |
1 |
| 39 |
34869917 | COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy. | 2021 Dec |
1 |
| 40 |
34884604 | Alternative RAS in Various Hypoxic Conditions: From Myocardial Infarction to COVID-19. | 2021 Nov 26 |
2 |
| 41 |
32089050 | Is hypertension in African-descent populations contributed to by an imbalance in the activities of the ACE2/Ang-(1-7)/Mas and the ACE/Ang II/AT1 axes? | 2020 Jan-Mar |
2 |
| 42 |
32228252 | COVID-19, ACE2, and the cardiovascular consequences. | 2020 May 1 |
2 |
| 43 |
32250244 | Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. | 2020 Apr 6 |
2 |
| 44 |
32301766 | Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. | 2020 Jun |
1 |
| 45 |
32314329 | [ACE2 and coronavirus - a question of balance and dynamics?] | 2020 Apr 17 |
1 |
| 46 |
32354022 | ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? | 2020 Apr 28 |
1 |
| 47 |
32367746 | ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. | 2020 Jul |
2 |
| 48 |
32387238 | Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients? | 2020 Jun |
2 |
| 49 |
32401442 | [Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?] | 2020 May 13 |
1 |
| 50 |
32412303 | Is the kidney a target of SARS-CoV-2? | 2020 Jun 1 |
1 |